|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Mortgage loans | ||||||||||||||||||||
| Commercial Loan | ||||||||||||||||||||
| Asset Pledged as Collateral | ||||||||||||||||||||
| Loans held-for-sale, fair value | ||||||||||||||||||||
| Commercial loans, at fair value - $49,254 and $55,376 pledged as collateral, respectively | ||||||||||||||||||||
| Residential mortgage loans | ||||||||||||||||||||
| Commercial Loan | ||||||||||||||||||||
| Residential Portfolio Segment | ||||||||||||||||||||
| Real estate securities, at fair value - $277,341 and $231,894 pledged as collateral, respectively | ||||||||||||||||||||
| VIE, Not Primary Beneficiary | ||||||||||||||||||||
| Real Estate Securities | ||||||||||||||||||||
| Residential Portfolio Segment | ||||||||||||||||||||
| Total real estate securities, at fair value - $277,341 and $231,894 pledged as collateral, respectively | ||||||||||||||||||||
| Commercial loans, at fair value | ||||||||||||||||||||
| Residential Portfolio Segment | ||||||||||||||||||||
| Investments in debt and equity of affiliates | ||||||||||||||||||||
| Investment, Affiliated Issuer | ||||||||||||||||||||
| Total investments in debt and equity of affiliates | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Total restricted cash | ||||||||||||||||||||
| Other assets - $0 and $319 pledged as collateral, respectively | ||||||||||||||||||||
| Asset Pledged as Collateral | ||||||||||||||||||||
| Total other assets - $0 and $319 pledged as collateral, respectively | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Securitized debt, at fair value | ||||||||||||||||||||
| Total securitized debt, at fair value | ||||||||||||||||||||
| Financing arrangements | ||||||||||||||||||||
| Total financing arrangements | ||||||||||||||||||||
| Convertible senior unsecured notes | ||||||||||||||||||||
| Senior unsecured notes | ||||||||||||||||||||
| Dividend payable | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ Equity | ||||||||||||||||||||
| Preferred stock - $227,991 aggregate liquidation preference | ||||||||||||||||||||
| Common stock, par value $0.01 per share; 450,000 shares of common stock authorized and 31,803 and 31,744 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings/(deficit) | ||||||||||||||||||||
| Stockholders' Equity | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity | ||||||||||||||||||||
Loading...
